Sun Pharmaceutical Industries Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1761, up 0.05% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.36% on the day, quoting at 26083.25. The Sensex is at 84758.67, down 0.36%. Sun Pharmaceutical Industries Ltd has dropped around 1.96% in last one month.

Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has dropped around 2.31% in last one month and is currently quoting at 23126.85, up 0.16% on the day. The volume in the stock stood at 17.39 lakh shares today, compared to the daily average of 18.59 lakh shares in last one month.

The benchmark January futures contract for the stock is quoting at Rs 1769.3, up 0.23% on the day. Sun Pharmaceutical Industries Ltd is down 4.18% in last one year as compared to a 10.11% gain in NIFTY and a 0.66% gain in the Nifty Pharma index.

The PE of the stock is 90.36 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

Sun Pharmaceutical Industries Ltd fell for a fifth straight session today. The stock is quoting at Rs 1712.2, down 0.29% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.17% on the day, quoting at 25897.6. The Sensex is at 84563.41, down 0.16%.Sun Pharmaceutical Industries Ltd has eased around 5.27% in last one month.Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has eased around 2.07% in last one month and is currently quoting at 22578.3, down 0.72% on the day. The volume in the stock stood at 9.85 lakh shares today, compared to the daily average of 20.24 lakh shares in last one month.

The benchmark December futures contract for the stock is quoting at Rs 1714.9, up 0.02% on the day. Sun Pharmaceutical Industries Ltd tumbled 9.23% in last one year as compared to a 9.53% rally in NIFTY and a 4.26% fall in the Nifty Pharma index.

The PE of the stock is 88.17 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

The American drug regulator had inspected the company?s facility from 8 September 2025 to 19 September 2025. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI).

?We continue to manufacture and supply approved products from the facility to the US market. We will work with the regulator to achieve fully compliant status,? the company said in a statement.

Sun Pharmaceutical Industries is the world?s leading specialty generics company with a presence in innovative medicines, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as global emerging markets.

The company had reported 2.6% rise in consolidated net profit to Rs 3,118 crore on a 8.6% increase in revenue to Rs 14,405.2 crore in Q2 FY26 as compared with Q2 FY25.

Powered by Capital Market - Live News

Sun Pharmaceutical Industries announced that the US FDA conducted an inspection at the Company's Baska facility from 8 September 2025 to 19 September 2025. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI).

Powered by Capital Market - Live News